Which HIV-1/2 antigen/antibody (Ag/Ab) test result indicates acute HIV-1 infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Acute HIV-1 Infection: Answer D

The correct answer is D) HIV-1 Ab negative, HIV-1 NAT positive, which represents the classic laboratory pattern of acute HIV-1 infection during the "window period" when viral RNA is detectable but antibodies have not yet developed. 1

Understanding the Diagnostic Timeline

The sequence of marker appearance in acute HIV-1 infection follows a predictable pattern:

  • HIV-1 RNA (NAT) becomes detectable first, typically 10-14 days after infection 1
  • p24 antigen appears 3-5 days after HIV RNA, usually between 14-22 days post-infection 1
  • HIV antibodies develop last, typically within the first 4 weeks following exposure but can take up to 6 months 1

Why Each Answer is Correct or Incorrect

Option A (HIV-1/2 Ab negative, p24 Ag negative): This represents either no infection or the very earliest stage of infection (within 10-14 days) when no markers are yet detectable—the true "eclipse period" 1. This does not indicate acute HIV-1 infection diagnostically.

Option B (HIV-1 Ab positive, HIV-2 Ab negative): This indicates established HIV-1 infection with seroconversion already complete, not acute infection 1. By the time antibodies are positive, the patient has moved beyond the acute phase.

Option C (HIV-1 Ab indeterminate, HIV-1 NAT negative): An indeterminate antibody result with negative NAT is more likely a false-positive antibody result or cross-reactivity rather than acute infection 1. True acute infection would show positive NAT.

Option D (HIV-1 Ab negative, HIV-1 NAT positive): This is the definitive pattern of acute HIV-1 infection 1. The laboratory diagnosis of primary (acute) HIV-1 infection is based on detection of HIV-1 RNA (typically >100,000 copies/mL) in the absence of antibodies 1.

Clinical Significance and Testing Algorithm

  • When acute HIV infection is suspected clinically, HIV RNA testing should be performed after a negative initial antibody and/or antigen test 1
  • The current CDC-recommended algorithm uses fourth-generation Ag/Ab combination assays as initial screening, followed by HIV-1/HIV-2 antibody differentiation 1
  • If the differentiation assay is negative (antibodies not detected), NAAT is recommended to rule out acute HIV-1 infection 1
  • HIV-1 qualitative NAAT is recommended in specific cases based on the antibody/antigen and differentiation test results 1

Important Caveats

  • There is a 10-14 day period after infection when no markers are detectable; testing another specimen 2-4 weeks later should be considered if initial tests are negative but clinical suspicion remains high 1
  • Low-level positive viral loads (<5,000 copies/mL) outside the acute infection setting may represent false positives and should prompt retesting of a second specimen 1
  • If NAAT is used to diagnose acute HIV-1 infection, document subsequent HIV-1 seroconversion by conventional serologic testing 1
  • Fourth-generation assays detect p24 antigen and can identify some but not all cases of acute infection—they miss approximately 27-36% of acute infections that NAT would detect 2, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

An improved HIV antigen/antibody prototype assay for earlier detection of acute HIV infection.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.